In summary, XPO1 inhibition primes cancer cells for NK cell mediated cytotoxicity via HLA-E downregulation, and SINEs in combination with NK cell directed therapies has potential to promote anti-tumour responses in patients. The gene discussed is XPO1; the disease is cancer.